In our latest episode, host Dr. Rob Rothman interviews Greg Kunst, CEO of Aurion Biotech, to delve into the forefront of cell therapy for corneal disease. Join us to discover:

• Greg's journey from pivotal roles at Alcon and Glaukos to leading Aurion Biotech
• The innovative allogenic cell therapy technology developed by Aurion
• How this technology addresses the global shortage of corneal tissue
• Insights into the challenges and breakthroughs in scaling production and securing market approval
• Future applications of cell therapy in ophthalmology beyond corneal endothelial disease

Don't miss this fascinating conversation on the future of medical innovation in ophthalmology! Listen to the episode and subscribe to the OIS Podcast for more updates on the latest trends in eye care and medical technology.